Clinical Trials Directory

Trials / Completed

CompletedNCT04084483

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
238 (actual)
Sponsor
Kowa Research Institute, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.

Conditions

Interventions

TypeNameDescription
DRUGK-161K-161 alternate dosage
OTHERPlacebo (Vehicle)Placebo solution

Timeline

Start date
2019-08-04
Primary completion
2020-01-09
Completion
2020-01-09
First posted
2019-09-10
Last updated
2023-03-15
Results posted
2023-03-15

Locations

4 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04084483. Inclusion in this directory is not an endorsement.

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease (NCT04084483) · Clinical Trials Directory